Stock listing

NASDAQ:HOWL Werewolf Therapeutics, Inc. Stock

Home listing (NASDAQ) of Werewolf Therapeutics, Inc.

Follow Werewolf Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:HOWL

$0.947 USD -0.083 (-8.1%)

Close on Nov 20, 2026

Past year +10.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.930 – $0.990 USDNov 20, 2026
Volume
373,048 sharesNov 20, 2026
Market cap
$46.01M USDAt the close on Nov 20, 2026 · price × 48.60M shares outstanding
52-week range
$0.270 – $1.200 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$5.43M USDMedian day 477,440 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Werewolf Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:HOWL · Home$0.947 USD-0.083 (-8.1%)373,048$0.955$0.990$0.930$1.030Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:HOWL · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.947-0.083-8.1%$0.955$0.990$0.930373,048
$1.030-0.020-1.9%$1.050$1.150$0.9801,850,429
$1.050+0.059+6.0%$0.968$1.050$0.9651,083,152
$0.991+0.011+1.1%$0.975$1.010$0.950724,982
$0.980+0.0000.0%$0.980$1.010$0.980317,207
$0.980-0.009-0.9%$1.000$1.003$0.978151,666
$0.989+0.019+1.9%$0.970$0.990$0.970138,343
$0.970-0.040-4.0%$1.010$1.010$0.970217,806
$1.0100.0000.0%$1.020$1.069$1.000334,533
$1.010-0.010-1.0%$1.020$1.030$0.983176,558
$1.020-0.070-6.4%$1.060$1.070$1.000300,783
$1.090+0.020+1.9%$1.080$1.100$1.050301,354
$1.070+0.020+1.9%$1.040$1.080$1.030232,240
$1.050+0.064+6.5%$0.986$1.060$0.986272,009
$0.986-0.114-10.4%$1.090$1.090$0.970415,476
$1.100+0.040+3.8%$1.080$1.100$1.050398,718
$1.060+0.020+1.9%$1.030$1.080$1.020388,391
$1.040+0.059+6.1%$0.990$1.050$0.960306,791
$0.981+0.001+0.1%$0.990$1.000$0.950477,440
$0.980-0.030-3.0%$1.010$1.030$0.980209,936
$1.010-0.020-1.9%$1.010$1.050$1.000184,155
$1.030-0.020-1.9%$1.050$1.060$1.010199,374
$1.050+0.010+1.0%$1.030$1.090$1.030485,738
$1.040+0.060+6.1%$0.979$1.055$0.979378,846
$0.980-0.017-1.7%$1.010$1.010$0.970309,200
$0.997+0.017+1.7%$0.962$1.018$0.962426,200
$0.980-0.011-1.1%$0.990$1.025$0.966664,000
$0.991+0.009+0.9%$1.000$1.010$0.970353,200
$0.982+0.002+0.2%$0.980$1.020$0.960811,200
$0.980+0.070+7.7%$0.930$0.990$0.920704,600
$0.910-0.010-1.1%$0.920$0.928$0.907631,300
$0.9200.0000.0%$0.916$0.925$0.908381,600
$0.920-0.010-1.1%$0.940$0.940$0.910278,200
$0.930+0.002+0.2%$0.930$0.950$0.910237,700
$0.928+0.046+5.2%$0.890$0.940$0.890470,900
$0.882-0.040-4.3%$0.920$0.925$0.881299,000
$0.922+0.012+1.3%$0.910$0.940$0.890828,200
$0.910-0.020-2.2%$0.940$0.950$0.880970,500
$0.930-0.030-3.1%$0.970$0.970$0.925699,300
$0.960-0.021-2.1%$0.975$0.983$0.960454,900
$0.981-0.008-0.8%$0.985$0.990$0.967227,500
$0.989+0.007+0.7%$0.974$0.990$0.970316,500
$0.982+0.002+0.2%$0.990$0.995$0.971374,800
$0.980+0.015+1.6%$0.985$0.990$0.960475,600
$0.965+0.002+0.2%$0.967$1.010$0.9601,226,200
$0.963+0.044+4.8%$0.940$0.980$0.935583,900
$0.919-0.061-6.2%$0.960$0.985$0.9191,508,600
$0.980+0.022+2.3%$0.951$0.982$0.9231,202,700
$0.958-0.024-2.4%$0.970$0.995$0.930969,800
$0.982-0.007-0.7%$0.970$1.020$0.960549,000
$0.989+0.024+2.5%$0.960$0.989$0.950900,400
$0.965-0.015-1.5%$0.975$0.990$0.950867,100
$0.980+0.014+1.4%$0.960$0.990$0.943663,400
$0.966+0.022+2.3%$0.940$0.967$0.930487,400
$0.944-0.054-5.4%$0.970$1.020$0.9331,330,500
$0.998+0.040+4.2%$0.943$0.998$0.9401,303,700
$0.958+0.017+1.8%$0.917$0.968$0.912982,600
$0.941-0.002-0.2%$0.935$0.949$0.9001,268,300
$0.943-0.028-2.9%$0.975$1.030$0.9272,333,800
$0.971-0.018-1.8%$0.990$0.998$0.9142,217,800
$0.989+0.099+11.1%$0.900$1.050$0.89811,618,700
$0.890+0.007+0.8%$0.866$0.934$0.8406,432,712
$0.883+0.009+1.1%$0.850$0.900$0.81112,041,910
$0.874+0.443+102.8%$0.980$1.050$0.860296,734,500
$0.431+0.022+5.4%$0.422$0.440$0.40366,021,400
Ticker
NASDAQ:HOWL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Werewolf Therapeutics, Inc. news

Werewolf Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
7 in the last 12 months · 67 in all · newest Nov 9, 2026 · oldest 2021
Decks
10 decks · latest Nov 10, 2026

Where Werewolf Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:HOWL · Home listing · This pageNASDAQUnited StatesUSD
BOATS:HOWLBOATSUnited StatesUSD

Valuation

Price/book 6.8× against a median of 5.1×: 7th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$4.14M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
6.8×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.55

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Werewolf Therapeutics, Inc. · NASDAQ:HOWLUS$46.01MUS$4.14Mn/an/an/a6.8×n/a0.0×1.55
THX Pharma · EURONEXT:ALTHXUS$47.23MUS$30.92Mn/an/an/a14.5×n/a0.9×n/a
FluoGuide A/S · OMXSTO:FLUOUS$47.17MUS$43.89Mn/a5,538×n/a10.5×n/a0.9×n/a
Rafael Holdings, Inc. · NYSE:RFLUS$47.10MUS$25.00Mn/a28.6×n/a0.7×n/a0.0×0.92
Bio-fd&c Co. Ltd · KRX:251120US$46.73MUS$5.29M9.8×0.4×0.9×0.9×32.8%0.0×n/a
Andros Pharmaceuticals Co., Ltd. · TPEX:6917US$46.01MUS$35.88Mn/a213×n/a3.1×−969.3%0.0×n/a
MegaPro Biomedical Co., Ltd. · TPEX:6827US$45.95MUS$43.30Mn/an/an/a7.0×n/a0.0×n/a
SunBio, Inc. · KRX:067370US$45.82MUS$42.92M14.2×4.6×8.9×2.0×34.6%0.0×n/a
Apollomics Inc. · NASDAQ:APLMUS$45.28MUS$42.65Mn/a5.0×n/an/a−128.7%n/a1.02
Zelluna ASA · OSL:ZLNAUS$45.02MUS$38.83Mn/an/an/a5.1×n/a0.0×n/a
Oncoinvent ASA · OSL:ONCINUS$44.76MUS$33.80Mn/a14.3×n/a5.4×−673.1%0.0×n/a
Median of the othersUS$45.98MUS$37.36M12.0×14.3×4.9×5.1×−128.7%0.0×0.97

Forecasts

Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
7.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.89 · 1 analyst

Team and board

Officers

OfficerRole
Daniel J. HicklinPresident, Chief Executive Officer, and Board member
Michael UrbanVice President of Finance and Corporate Controller

Board

DirectorRole
Anil SinghalBoard member
Briggs MorrisonBoard member
Daniel J. HicklinPresident, Chief Executive Officer, and Board member
Meeta ChatterjeeBoard member
Michael B. AtkinsBoard member
Michael ShermanBoard member

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · After close+1.1%
Q2 2026Jul 31, 2026 · Before open−29.4%
Q1 2026May 8, 2026+6.6%
Q4 2025Mar 27, 2026 · Before open−9.5%
Q3 2025Nov 4, 2025 · Before open−7.6%
Q2 2025Aug 14, 2025 · Before open−2.2%
Q1 2025May 8, 2025 · Before open−5.5%
Q4 2024Mar 11, 2025+0.4%
Q3 2024Nov 7, 2024 · Before open−8.2%
Q2 2024Aug 8, 2024 · Before open+8.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 3, 2024 · Before open−0.2%
Q4 2023Mar 7, 2024 · Before open−4.0%
Q3 2023Nov 14, 2023 · After close0.0%
Q2 2023Aug 10, 2023 · Before open+4.0%
Q1 2023May 11, 2023 · Before open−8.9%
Q4 2022Mar 23, 2023 · Before open−5.2%
Q3 2022Nov 10, 2022 · Before open+3.1%
Q2 2022Aug 11, 2022 · Before open+14.0%
Q1 2022May 10, 2022 · Before open+10.9%
Q4 2021Mar 24, 2022 · Before open−4.4%

Open Events

Decks

DeckKindSlidesDate
Merger or Acquisition (November 2026)Merger or acquisition36 slidesNov 10, 2026
Merger or Acquisition (August 2026)Merger or acquisition24 slidesAug 21, 2026
Investor Presentation (December 2025)Investor deck41 slidesDec 18, 2025
Investor Presentation (August 2025)Investor deck46 slidesAug 14, 2025
Investor Presentation (May 2025)Investor deck57 slidesMay 8, 2025
Investor Presentation (November 2024)Investor deck53 slidesNov 12, 2024
ASCO 2024Conference24 slidesJun 3, 2024
Investor Presentation (January 2024)Investor deck31 slidesJan 8, 2024
Technical Presentation (November 2023)Technical15 slidesNov 3, 2023
Investor Presentation (September 2023)Investor deck22 slidesSep 18, 2023

Open Decks

IPO

Priced at US$16.00 a share on Apr 29, 2021.

Price
US$16.00 a share
Shares offered
7,500,000 shares of common stock
Offering size
US$120 million
Underwriters' option
Up to 1,125,000 more shares
Underwriters
Jefferies, SVB Leerink, Evercore ISI, H.C. Wainwright & Co. · In the order on the cover
Shares delivered
On or about May 4, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 26, 2021
Filed publiclyApr 8, 2021
Amended onceApr 26, 2021
Shares registered with an exchangeApr 27, 2021
Declared effective by the SECApr 29, 2021
Final prospectus, with the priceApr 30, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Apr 30, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue01.89M19.9M16.4M4.15M00
Cost of revenue1.63M1.81M1.76M2.51M735.0K777.0K463.0K
Gross profit-1.63M71.0K18.2M16.4M-735.0K-777.0K-463.0K
Research and development44.8M56.4M41.8M53.8M35.3M16.6M6.34M
Selling, general and administrative15.8M19.0M18.7M18.7M14.8M5.76M3.60M
Operating income-60.7M-73.6M-40.5M-56.1M-50.1M-22.4M-9.94M
Depreciation and amortization1.63M1.81M1.76M1.10M216.0K150.0K25.0K
EBITDA-59.0M-71.8M-38.7M-55.0M-49.9M-22.3M-9.91M
Interest expense5.27M4.66M3.14M0216.0K101.0K372.0K
Income before tax-60.8M-70.5M-37.4M-53.8M-50.0M-15.0M-10.2M
Income tax01.60M-2.25M-216.0K-101.0K742.0K
Net income-60.8M-70.5M-37.4M-53.8M-50.0M-15.0M-11.0M
Earnings per share, basic-1.32-1.63-1.05-1.86-10.94-28.08-0.38
Earnings per share, diluted-1.33-1.63-1.05-1.86-10.94-28.08

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents57.0M111.0M134.3M129.3M157.5M92.6M17.9M
Receivables1.35M6.93M
Inventory2
Current assets58.6M113.1M138.4M140.2M161.1M92.9M18.1M
Property, plant and equipment4.69M6.32M7.96M8.99M2.91M651.0K3.41M
Total assets69.4M126.9M174.8M160.2M179.3M96.4M21.7M
Accounts payable754.0K3.04M1.34M1.22M2.04M1.02M633.0K
Current liabilities36.1M15.2M19.4M24.0M11.9M5.28M2.04M
Long-term debt26.1M32.7M
Total debt32.1M32.1M40.0M14.7M15.7M2.54M3.14M
Total liabilities44.6M53.5M63.5M37.9M26.5M7.18M11.9M
Shareholders' equity24.8M73.4M111.4M122.3M152.8M-51.9M9.77M
Shares outstanding48.6M44.8M39.1M31.4M27.3M1.18M28.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-60.3M-56.2M-32.6M-40.6M-42.9M-18.6M-9.54M
Capital spending0-254.0K-769.0K-3.61M-498.0K-560.0K-266.0K
Free cash flow-60.3M-56.4M-33.4M-44.2M-43.4M-19.2M-9.81M
Cash from investing0-254.0K-769.0K-3.61M-498.0K-560.0K-266.0K
Cash from financing6.03M13.1M58.4M15.9M109.4M93.9M21.9M
Share buybacks16.0M109.4M
Change in cash-54.3M-43.4M25.0M-28.3M66.1M74.7M12.1M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
EFFECT · Notice that a registration is effectiveNov 13, 2026Other filingsSEC
424B3 · ProspectusNov 12, 2026Offer documentSEC
S-4/A · Registration statement, amendedNov 10, 2026Offer documentSEC
425Nov 9, 2026Other filingsSEC
8-K · Current reportNov 9, 2026Current reportSEC
S-4/A · Registration statement, amendedOct 26, 2026Offer documentSEC
S-4 · Registration statementSep 22, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeSep 21, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
425Aug 21, 2026Other filingsSEC
8-K · Current reportAug 21, 2026Material contractSEC
8-K · Current reportAug 20, 2026Material contractSEC
10-Q · Quarterly reportJul 31, 2026Quarterly reportSEC
8-K · Current reportJul 31, 2026ResultsSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 2, 2026Big-stake noticeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 26, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 22, 2026Big-stake noticeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 15, 2026Big-stake noticeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 12, 2026Big-stake noticeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 5, 2026Big-stake noticeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
144 · Notice of proposed saleApr 29, 2026Other filingsSEC
144 · Notice of proposed saleApr 29, 2026Other filingsSEC
144 · Notice of proposed saleApr 29, 2026Other filingsSEC
144 · Notice of proposed saleApr 29, 2026Other filingsSEC
144 · Notice of proposed saleApr 29, 2026Other filingsSEC
144 · Notice of proposed saleApr 29, 2026Other filingsSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
10-K · Annual reportMar 27, 2026Annual reportSEC
8-K · Current reportMar 27, 2026ResultsSEC
3 · Initial statement of ownershipMar 13, 2026Insider tradeSEC
8-K · Current reportFeb 24, 2026Current reportSEC
8-K · Current reportFeb 13, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2026Big-stake noticeSEC
8-K · Current reportFeb 6, 2026Current reportSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 16, 2026Big-stake noticeSEC
4 · Change in ownershipJan 15, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 29, 2025Big-stake noticeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
8-K · Current reportDec 18, 2025Current reportSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
144 · Notice of proposed saleDec 10, 2025Other filingsSEC
144 · Notice of proposed saleDec 10, 2025Other filingsSEC
144 · Notice of proposed saleDec 10, 2025Other filingsSEC
144 · Notice of proposed saleDec 10, 2025Other filingsSEC
144 · Notice of proposed saleDec 10, 2025Other filingsSEC
144 · Notice of proposed saleDec 10, 2025Other filingsSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 3, 2025Big-stake noticeSEC
144 · Notice of proposed saleDec 3, 2025Other filingsSEC
144 · Notice of proposed saleDec 3, 2025Other filingsSEC
144 · Notice of proposed saleDec 3, 2025Other filingsSEC
144 · Notice of proposed saleDec 3, 2025Other filingsSEC
144 · Notice of proposed saleDec 3, 2025Other filingsSEC
144 · Notice of proposed saleDec 3, 2025Other filingsSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 17, 2025Big-stake noticeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
144 · Notice of proposed saleNov 10, 2025Other filingsSEC
144 · Notice of proposed saleNov 10, 2025Other filingsSEC
144 · Notice of proposed saleNov 10, 2025Other filingsSEC
144 · Notice of proposed saleNov 10, 2025Other filingsSEC
144 · Notice of proposed saleNov 10, 2025Other filingsSEC
144 · Notice of proposed saleNov 10, 2025Other filingsSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 6, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 4, 2025Big-stake noticeSEC
144 · Notice of proposed saleNov 4, 2025Other filingsSEC
144 · Notice of proposed saleNov 4, 2025Other filingsSEC
144 · Notice of proposed saleNov 4, 2025Other filingsSEC
144 · Notice of proposed saleNov 4, 2025Other filingsSEC
144 · Notice of proposed saleNov 4, 2025Other filingsSEC
144 · Notice of proposed saleNov 4, 2025Other filingsSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
8-K · Current reportNov 4, 2025ResultsSEC
4 · Change in ownershipNov 3, 2025Insider tradeSEC
4 · Change in ownershipNov 3, 2025Insider tradeSEC
4 · Change in ownershipNov 3, 2025Insider tradeSEC
144 · Notice of proposed saleOct 30, 2025Other filingsSEC
144 · Notice of proposed saleOct 30, 2025Other filingsSEC
144 · Notice of proposed saleOct 30, 2025Other filingsSEC
144 · Notice of proposed saleOct 30, 2025Other filingsSEC
144 · Notice of proposed saleOct 30, 2025Other filingsSEC
144 · Notice of proposed saleOct 30, 2025Other filingsSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC

This page holds 200 of 457 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Werewolf Therapeutics, Inc.’s releases

Common shares
48,601,487
Fully diluted
48,601,487

Fully diluted

LineShares
Common shares48,601,487

Share count over time

CountShares
Nov 22, 202648,601,487

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Balyasny Asset Management L.P.3.04M6.3%US$2.8MSep 30, 2026
ADAR1 Capital Management, LLC2.02M4.2%US$1.87MSep 30, 2026
Vanguard1.52M3.1%US$1.4MSep 30, 2026
Lynx1 Capital Management LP658K1.4%US$607KSep 30, 2026
Sphera Funds Management LTD.627K1.3%US$578KSep 30, 2026
DC Funds, LP589K1.2%US$543KSep 30, 2026
Jane Street565K1.2%US$521KSep 30, 2026
Citadel554K1.1%US$511KSep 30, 2026
Renaissance Technologies551K1.1%US$508KSep 30, 2026
Hrt Financial LP415K0.85%US$382KSep 30, 2026
All 44 holders
HolderSharesOf the companyValueAs of
Geode Capital407K0.84%US$376KSep 30, 2026
Acadian Asset Management LLC317K0.65%US$291KSep 30, 2026
XTX Topco Ltd210K0.43%US$193KSep 30, 2026
Bank of America172K0.35%US$158KSep 30, 2026
BlackRock153K0.32%US$141KSep 30, 2026
Covestor Ltd134K0.28%US$124KSep 30, 2026
State Street119K0.25%US$110KSep 30, 2026
Northern Trust97,4090.20%US$89,840Sep 30, 2026
Virtu Financial LLC90,7490.19%US$84,000Sep 30, 2026
Alyeska Investment Group, L.P.86,5540.18%US$79,829Sep 30, 2026
Morgan Stanley69,6230.14%US$64,213Sep 30, 2026
Vontobel Holding Ltd.60,0000.12%US$55,338Sep 30, 2026
StoneX Group Inc.54,8560.11%US$51,099Sep 30, 2026
Vilga Financial Planning LLC53,4230.11%US$49,272Sep 30, 2026
UBS41,4420.09%US$38,210Sep 30, 2026
Prudential Financial Inc37,4000.08%US$34,494Sep 30, 2026
Goldman Sachs28,5330.06%US$26,316Sep 30, 2026
JPMorgan24,3930.05%US$22,197Sep 30, 2026
LPL Financial LLC23,0690.05%US$21,277Sep 30, 2026
Two Sigma20,5780.04%US$18,979Sep 30, 2026
Barclays20,3900.04%US$18,806Sep 30, 2026
Certuity, LLC15,0000.03%US$13,835Sep 30, 2026
HBK Sorce Advisory LLC13,7370.03%US$14,012Sep 30, 2026
Larson Financial Group LLC13,0520.03%US$12,038Sep 30, 2026
Citigroup Inc11,9710.02%US$11,041Sep 30, 2026
Marest Capital, LLC10,8700.02%US$10,025Sep 30, 2026
Boothbay Fund Management, LLC10,0000.02%US$9,223Sep 30, 2026
Osaic Holdings, Inc.8,6250.02%US$7,935Sep 30, 2026
Financial Perspectives, Inc6,7500.01%US$6,226Sep 30, 2026
Jones Financial Companies Lllp3,000<0.01%US$2,877Sep 30, 2026
Tower Research Capital LLC (TRC)1,366<0.01%US$1,260Sep 30, 2026
BNP Paribas790<0.01%US$729Sep 30, 2026
SBI Securities Co., Ltd.130<0.01%US$120Sep 30, 2026
Optiver Holding B.V.22<0.01%US$20Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund874K1.8%US$314KJun 30, 2026
Vanguard Extended Market Index Fund344K0.71%US$124KJun 30, 2026
Fidelity Extended Market Index Fund215K0.44%US$96,590May 31, 2026
Fidelity Total Market Index Fund54,5770.11%US$24,560May 31, 2026
Fidelity Series Total Market Index Fund42,6280.09%US$19,183May 31, 2026
Fidelity Nasdaq Composite Index Fund23,3470.05%US$10,506May 31, 2026
Blackstone Alternative Multi-Strategy Fund500<0.01%US$180Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Luke Evnin
Director
Sale107,429USD 0.31US$33,303Jul 7, 2026
Luke Evnin
Director
Sale35,770USD 0.32US$11,446Jul 6, 2026
Luke Evnin
Director
Sale157,084USD 0.30US$47,125Jun 29, 2026
Ra Capital Management, L.P.
10% owner
Sale389,216USD 0.35US$136KJun 17, 2026
Ra Capital Management, L.P.
10% owner
Sale27,695USD 0.35US$9,693Jun 17, 2026
Ra Capital Management, L.P.
10% owner
Sale139,686USD 0.37US$51,684Jun 16, 2026
Ra Capital Management, L.P.
10% owner
Sale9,939USD 0.37US$3,677Jun 16, 2026
Ra Capital Management, L.P.
10% owner
Sale120,216USD 0.39US$46,884Jun 15, 2026
Ra Capital Management, L.P.
10% owner
Sale8,554USD 0.39US$3,336Jun 15, 2026
Ra Capital Management, L.P.
10% owner
Sale159,119USD 0.40US$63,648Jun 12, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Ra Capital Management, L.P.
10% owner
Sale11,322USD 0.40US$4,529Jun 12, 2026
Kolchinsky Peter
10% owner
Sale245,066USD 0.38US$93,125Jun 11, 2026
Kolchinsky Peter
10% owner
Sale17,437USD 0.38US$6,626Jun 11, 2026
Kolchinsky Peter
10% owner
Sale42,872USD 0.37US$15,863Jun 10, 2026
Kolchinsky Peter
10% owner
Sale3,051USD 0.37US$1,129Jun 10, 2026
Kolchinsky Peter
10% owner
Sale345,235USD 0.37US$128KJun 9, 2026
Kolchinsky Peter
10% owner
Sale24,565USD 0.37US$9,089Jun 9, 2026
Luke Evnin
Director
Sale76,928USD 0.37US$28,463Jun 9, 2026
Luke Evnin
Director
Sale60,547USD 0.40US$24,219Jun 8, 2026
Luke Evnin
Director
Sale24,946USD 0.40US$9,978Jun 5, 2026
Luke Evnin
Director
Sale20,072USD 0.44US$8,832Jun 4, 2026
Luke Evnin
Director
Sale29,749USD 0.42US$12,495Jun 3, 2026
Luke Evnin
Director
Sale29,595USD 0.45US$13,318Jun 2, 2026
Luke Evnin
Director
Sale80,459USD 0.47US$37,816Jun 1, 2026
Luke Evnin
Director
Sale32,556USD 0.45US$14,650May 29, 2026
Luke Evnin
Director
Sale27,698USD 0.46US$12,741May 28, 2026
Luke Evnin
Director
Sale80,852USD 0.48US$38,809May 27, 2026
Luke Evnin
Director
Sale67,950USD 0.47US$31,937May 26, 2026
Luke Evnin
Director
Sale87,425USD 0.45US$39,341May 22, 2026
Luke Evnin
Director
Sale36,387USD 0.42US$15,283May 21, 2026
Luke Evnin
Director
Sale85,895USD 0.43US$36,935May 20, 2026
Luke Evnin
Director
Sale62,970USD 0.45US$28,337May 19, 2026
Luke Evnin
Director
Sale22,184USD 0.50US$11,092May 18, 2026
Luke Evnin
Director
Sale44,679USD 0.54US$24,127May 13, 2026
Luke Evnin
Director
Sale67,885USD 0.64US$43,446May 12, 2026
Ra Capital Management, L.P.
10% owner
Sale94,432USD 0.64US$60,436May 12, 2026
Ra Capital Management, L.P.
10% owner
Sale6,719USD 0.64US$4,300May 12, 2026
Luke Evnin
Director
Sale33,948USD 0.67US$22,745May 11, 2026
Ra Capital Management, L.P.
10% owner
Sale81,678USD 0.67US$54,724May 11, 2026
Ra Capital Management, L.P.
10% owner
Sale5,812USD 0.67US$3,894May 11, 2026
Luke Evnin
Director
Sale305,741USD 0.70US$214KMay 8, 2026
Ra Capital Management, L.P.
10% owner
Sale351,514USD 0.71US$250KMay 8, 2026
Ra Capital Management, L.P.
10% owner
Sale25,012USD 0.71US$17,759May 8, 2026
Luke Evnin
Director
Sale79,086USD 0.63US$49,824May 7, 2026
Luke Evnin
Director
Sale14,635USD 0.66US$9,659May 6, 2026
Luke Evnin
Director
Sale6,860USD 0.69US$4,733May 5, 2026
Luke Evnin
Director
Sale47,963USD 0.72US$34,533May 4, 2026
Luke Evnin
Director
Sale58,394USD 0.73US$42,628May 1, 2026
Luke Evnin
Director
Sale168,262USD 0.72US$121KApr 30, 2026
Luke Evnin
Director
Sale56,559USD 0.69US$39,026Apr 29, 2026

This page holds 50 of 52 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Balyasny Asset Management L.P.6.26%3.04MSep 30, 2026Schedule 13G
MOLL PETER5.20%2.54MSep 18, 2026Schedule 13G
Ra Capital Management, L.P.4.10%1.99MJun 30, 2026Schedule 13D
ANSBERT GADICKE3.80%1.83MMay 8, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Apr 29, 2021 – May 12, 2025 · Past
Briggs Morrison
Other companies: CRISPR Therapeutics AG (Director · Since at least Jun 5, 2025); Arvinas, Inc. (Chair of the Arvinas Board of Directors · Since at least Sep 26, 2018); Carisma Therapeutics, Inc. (Director · Mar 7, 2023 – Jun 26, 2024 · Past); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 17, 2021 · Past); Oncorus Inc (Director · Oct 1, 2020 – Oct 1, 2020 · Past); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 11, 2020 · Past); Syndax Pharmaceuticals, Inc. (Director · Mar 2, 2016 – Feb 7, 2024 · Past)
Director · Since at least Apr 29, 2021
Michael Sherman
Other companies: Aktis Oncology, Inc. (Director · Since at least Jan 8, 2026); Chimerix Inc (Chief Executive Officer, Director · Jun 20, 2024 – Apr 21, 2025 · Past)
Director · Since at least May 24, 2024
Alon Lazarus
Other companies: Keros Therapeutics, Inc. (Director · Apr 7, 2020 – Apr 13, 2020 · Past)
Director · Since at least Dec 23, 2020
Anil Singhal
Other companies: TriSalus Life Sciences, Inc. (Director · Aug 10, 2023 – Aug 13, 2024 · Past)
Board member · Since at least Feb 19, 2025
Steven H Bloom
Other companies: Verastem, Inc. (Chief Strategy Officer · Nov 8, 2017 – Jan 3, 2019 · Past)
Chief Business Officer · Apr 16, 2025 – May 1, 2025 · Past
Daniel J. HicklinPresident, Chief Executive Officer, and Board member · Since at least Dec 8, 2020
Ellen LubmanChief Business Officer · Jan 2, 2024 – Jan 2, 2025 · Past
Luke EvninDirector · Since at least Apr 27, 2026
Meeta ChatterjeeDirector · Since at least Jun 12, 2025
All 16 people
PersonSeat
Michael AtkinsBoard member · Since at least Jan 4, 2024
Michael UrbanVice President of Finance and Corporate Controller · Since at least Feb 13, 2026
Randi IsaacsChief Medical Officer · Nov 9, 2020 – Jan 2, 2025 · Past
Reid LeonardChief Operating Officer · Dec 8, 2020 – Jan 3, 2023 · Past
Sakae AsanumaDirector · Dec 23, 2020 – Apr 29, 2021 · Past
Timothy W TrostChief Financial Officer · Jan 2, 2024 – Jan 2, 2025 · Past

Open People

Log in to ask 6ix AI your own questions about Werewolf Therapeutics, Inc.